|
TUBGCP5 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62436730732907E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
<1E-12 |
| Normal-vs-Stage2 |
8.58699999994883E-07 |
| Normal-vs-Stage3 |
1.30340183090993E-13 |
| Normal-vs-Stage4 |
1.83264514674875E-12 |
| Stage1-vs-Stage2 |
7.114000E-02 |
| Stage1-vs-Stage3 |
7.103400E-01 |
| Stage1-vs-Stage4 |
1.468200E-01 |
| Stage2-vs-Stage3 |
8.646000E-02 |
| Stage2-vs-Stage4 |
1.639960E-02 |
| Stage3-vs-Stage4 |
3.261600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
1.120050E-03 |
| Normal-vs-Asian |
1.26132437827664E-12 |
| Caucasian-vs-AfricanAmerican |
1.518830E-01 |
| Caucasian-vs-Asian |
5.561000E-01 |
| AfricanAmerican-vs-Asian |
1.101950E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
8.91509088774001E-14 |
| Normal-vs-Female |
1.62436730732907E-12 |
| Male-vs-Female |
9.625600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62447832963153E-12 |
| Normal-vs-Age(41-60Yrs) |
1.58761892521397E-14 |
| Normal-vs-Age(61-80Yrs) |
8.04579736168876E-11 |
| Normal-vs-Age(81-100Yrs) |
1.117750E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.419000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
9.891900E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.557400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.367200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.170800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.550200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.074590E-01 |
| Classical-VS-Follicular |
1.203560E-01 |
| Classical-VS-Other |
2.515000E-01 |
| Classical-VS-Normal |
1.62458935193399E-12 |
| Tall-VS-Follicular |
9.461000E-03 |
| Tall-VS-Other |
7.223600E-01 |
| Tall-VS-Normal |
6.59660104318505E-11 |
| Follicular-VS-Other |
1.449230E-01 |
| Follicular-VS-Normal |
2.29180000532736E-08 |
| Other-VS-Normal |
5.77330000000043E-05 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.87228010872786E-12 |
| Normal-vs-N1 |
1.52100554373646E-14 |
| N0-vs-N1 |
1.243940E-03 |
|
|
